Role of macrophage targeting in the antitumor activity of trabectedin.

By G. Germano, R. Frapolli, Cristina Belgiovine, A. Anselmo, Samantha Pesce, Manuela Liguori, E. Erba, S. Uboldi, M. Zucchetti, F. Pasqualini and 14 more. Cancer Cell, 2013

840 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/69baf0b0176211ae403975d97b1ce1b95492dc76

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. A. Mantovani
2. P. Allavena
3. J. Pollard
4. C. Garlanda
5. R. Noy
6. Jong-Sup Bae
7. Jaehong Kim
8. V. Bronte

In Molecular Biology

1. A. Mantovani
2. J. Pollard
3. P. Allavena
4. Heather H Gustafson
5. S. Pun
6. Chayanon Ngambenjawong
7. Michele De Palma
8. C. Lewis

Citations in the corpus

• Progress in tumor-associated macrophage (TAM)-targeted therapeutics (2017, positive): “Mechanistically, trabectedin interacts with tumor necrosis factor-related apoptosis inducing ligand receptor 2 (TRAIL-R2) on mononuclear phagocytes leading to receptor clustering and subsequent caspase-8 dependent activation of apoptosis [154][155].”
• The spleen in local and systemic regulation of immunity (2013, background): “Trabectedin activates caspase-8dependent apoptosis, and its selectivity for monocytes is due to differential expression of signaling and decoy TRAIL receptors (Germano et al., 2013).”
• Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment (2014, background): “This compound can selectively deplete TAMs in tumor patients by activating the extrinsic apoptotic pathway via TRAIL receptors [115].”
• Macrophages in immunoregulation and therapeutics (2023, background): “One proposed mechanism for trabectedin’s anticancer action is lowering CCL2 levels, reducing the number of macrophages in tumor tissues.(379) The possibility of using chemotherapy to set up immune responses that kill tumor cells was also examined.”
• Tumor-associated macrophages: from mechanisms to therapy (2014, background): “Studies of lung metastasis show that upon their arrival at the target site, tumor cells together with associated platelets recruited via their expression of tissue factor form microclots and arrest in the target tissue vessels (Gil-Bernabé et al., 2012).”
• Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications (2019, background): “From the mouse models, treatment with antibodies against VEGF-C/VEGFR-3 or genetic ablation of heparanase significantly altered the lymphatic vessel phenotype and subsequently impaired the primary tumor growth and metastasis [101].”